• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Subconjunctival conbercept for the treatment of corneal neovascularization

    2023-06-17 06:52:18CunSunFangRuanShangLiJianQiangZhangYingJie

    Cun Sun, Fang Ruan, Shang Li, Jian-Qiang Zhang, Ying Jie

    1Department of Ophthalmology, Beijing Huimin Hospital,Beijing 100053, China

    2Department of Ophthalmology, Beijing You’an Hospital,Capital Medical University, Beijing 100054, China

    3Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University,Beijing Ophthalmology and Visual Sciences Key Lab, Beijing 100730, China

    Abstract● AIM: To investigate the effectiveness and safety of subconjunctival injection of conbercept in the treatment of corneal neovascularization (CNV).

    ● KEYWORDS: corneal neovascularization; conbercept;anti-vascular endothelial growth factor; subconjunctival injection

    INTRODUCTION

    Corneal neovascularization (CNV) is the in-growth of new immature vasculature from the limbus into the avascular corneal tissue, which could lead to the opacification of the transparent cornea.As a highly prevalent cause of blindness in the world, CNV affects over 1.4 million people annually,12% of whom suffer subsequent vision loss[1-2].To date,the treatment of CNV includes local use of glucocorticoids and non-steroid anti-inflammatory medications, laser photocoagulation, fine needle diathermy, photodynamic therapy, and conjunctival, limbal, and amniotic membrane transplantation, all with however suboptimal effectiveness[1,3].One potential explanation for the suboptimal effectiveness might be that none of these treatments targets the molecular mediators of angiogenesis.

    Recently, inhibitors of vascular endothelial growth factor(VEGF), which is the most important regulatory factor for angiogenesis, have shown good clinical application prospects and been approved for the treatment of neovascular fundus abnormalities[4].Existing pre-clinical and clinical research has shown the effectiveness of subconjunctival or corneal stromal injection of different anti-VEGF agents (e.g., bevacizumab,ranibizumab, and aflibercept) in the treatment of CNV[5-6].Conbercept (KH902; Chengdu Kanghong Biotech Co., China)is a recombinant fusion protein with key domains 2, 3, and 4 from VEGF receptors 1 and 2.Ⅰt has a high affinity for all VEGF isoforms as well as placental growth factors[7].In 2013,it was approved in China for the treatment of neovascular(wet) age-related macular degeneration and choroidal neovascularization secondary to pathological myopia[7].Whether conbercept could be used in the treatment of CNV is however largely unknown.The present study aimed thereforeto understand the effectiveness and safety of conberceptviasubconjunctival injection in modulating the characteristics of CNV.

    Table 1 Clinical characteristics of the 10 patients with corneal neovascularization

    SUBJECTS AND METHODS

    Ethical ApprovalThis study was additionally approved by the biomedical research ethics committee of Beijing Huimin Hospital (No.2018.1012).All recruited patients gave their written informed consent before their inclusion as participants in this study.

    Study ParticipantsThis is a case series study, including 10 patients with CNV who were consecutively recruited during December 2018-November 2019 in Beijing Huimin Hospital,Beijing, China.

    Ⅰnclusion criteria: age ≥18y, clinical diagnosis of CNV without active eye diseases, and neovascularization more than 2 mm into the corneal limbus.

    Exclusion criteria: corneal trauma, infection, or ophthalmic surgery during the past month; use of contact lenses during the past month; or severe systemic diseases.

    TreatmentLevofloxacin eye drops were applied four times a day for three days before the injection of conbercept.On the day of injection, we used proparacaine hydrochloride eye drops as anesthesia, iodophor solution to sterilize the skin around the eyes, and povidone-iodine solution to sterilize the conjunctival sac.We injected 0.1 mL of conbercept(10 mg/mL) into the corneoscleral limbus near the root of the new blood vessels.All injections were administered by the same ophthalmologist (Sun C).

    Study OutcomesVisual acuity and area, length, and diameter of neovascularization at five different time points (before treatment,1d, 1, 2wk, and 1mo after treatment), as well as systemic and ocular complications after treatment, were documented.Corneal images were taken at all five time points, using an anterior segment slit-lamp microscope at the magnification required to delineate the fine details of the vessels.

    Data AnalysisWe used Image pro plus 6.0 to measure the area, length, and diameter of neovascularization.Area was calculated by using the following formula: area(mm2)=CN/12×3.1416×[R2?(R?VL)2], where CN is the clock hours of neovascularization, R is the radius of the cornea, and VL is the longest vessel length, extending from the limbal vasculature[8].In terms of length, we identified three blood vessels with the greatest length in the densest quadrant of CNV and measured the greatest distance between the starting point of each vessel at the corneal limbus and anywhere along the vessel.We then calculated the mean value of the length of these three vessels as the measured length.In terms of diameter, we measured the diameters of all new blood vessels at the corneal limbus and calculated the average value as the diameter.

    Statistical AnalysisStatistical analysis was performed using SPSS 19.0.Shapiro-Wilk method was used to test the normality of data, and one-way repeated measure analysis of variance was used to compare data across the five time points.We also performed within-individual analysis to study the temporal trend of different parameters across the time points.Data are reported as mean±standard deviation (SD).AP<0.05 was considered statistically significant.

    RESULTS

    Clinical CharacteristicsAmong the 10 patients with CNV,all were male, with a mean age of 44±10.15y (Table 1).

    The mean±SD area of neovascularization was 42.46±12.80 mm2before treatment, and there was a statistically significant difference between all the time points after treatment and the time point before treatment (allP<0.05, Table 2, Figure 1).There was also a clearly declining area across the four different time points after treatment (F=31.373,P<0.001).

    The mean±SD length of neovascularization was 4.64±1.77 mm before treatment and there was a statistically significant difference between the length measured at 1, 2wk, as well as 1mo after treatment and the length measured before treatment(allP<0.01; Table 2, Figure 1).There was also a declining trend of length across the four time points after treatment(F=19.652,P<0.001).

    Figure 1 Outcomes of corneal neovascularization (CNV) parameters at five different time points A: CNV area; B: CNV length; C: CNV diameter.Compared with before treatment, aP<0.05, bP<0.01, cP<0.001.The significant therapeutic response which was evidenced as early as 1d, then peaked at 2wk, and reduced at 1mo.

    Figure 2 The effect of subconjunctival conbercept in patient 3, a 49-year-old man with chemical injury in the left eye complicated by corneal scarring, and neovascularization A: Baseline picture shows two main vessel branches emerging from the 12-o’clock and 5-o’clock position at the limbus and passing into the depressed scar in the corneal mid-periphery where it branched several times into smallercaliber vessels.B, C, D, E: 1d, 1, 2wk, and 1mo after subconjunctival conbercept.

    Table 2 Area, length, and diameter of neovascularization before and after subconjunctival conbercept

    The mean±SD diameter of neovascularization was 0.060±0.026 mm before treatment and there was a statistically significant difference between the diameter measured at 1wk,2wk, as well as 1mo after treatment and the diameter measured before treatment (allP<0.05; Table 2, Figure 1).There was also a declining trend of diameter across the four time points after treatment (F=16.661,P<0.001).

    The slit-lamp photographs of patient 3 were shown in Figure 2.

    DISCUSSION

    The formation of CNV is a complex process, involving vascular endothelial cells, keratinocytes, and inflammatory cells[9].Neovascular patterns can be separated into three groups, namely deep neovascularization overlying Descemet’s membrane (herpetic and luetic interstitial keratitis), stromal neovascularization (as a result of stromal keratitis), and vascular pannus (ocular surface disorders)[10].Multiple factors might contribute to the development of CNV.For instance,VEGF is the most important pro-angiogenic factor[2]and demonstrates a significantly increased concentration in the vascularized cornea[9].On the other hand, VEGF antagonists have been shown to reduce CNV in animal models[10], whereas anti-VEGF drugs have been shown to improve the survival rate of transplanted corneal grafts by restoring the “immune privilege”of the cornea[11].Subconjunctival bevacizumab,ranibizumab, and aflibercept crossed the blood and seemed to be effective in inhibiting CNV without causing epitheliopathy in an experimental rat model compared to the controls.No significant results were noted between these three anti-VEGF molecules, however, multiple-dose bevacizumab treatment seems to be more effective[11-12].

    Several anti-VEGF agents are currently used in clinical offlabel for the treatment of CNV, and most of them appear to be a safe, effective, and practical method[5,13-16].In the first report of human use of topical bevacizumab for CNV, two patients showed significant reductions in superficial and deep stromal neovascularization without impairment in the corneal endothelium[17].Others have also shown that perilimbal and intrastromal injection of bevacizumab before penetrating keratoplasty can improve surgical outcomes of high-risk patients[18].Ranibizumab, another monoclonal antibody against VEGF-A, has also been used to reduce CNV in both animal models and clinical studies[19-20].Aflibercept (VEGF TrapR1R2) has strong anti-VEGF activity and is a soluble fusion protein with binding domains for both VEGF receptors 1 and 2.Subconjunctival injection of aflibercept can reduce donor vascularization and improve graft survival in a high-risk graft murine model[21].However, Sellaet al[22]showed that a single subconjunctival aflibercept injection was ineffective to regress formed CNV.

    So far, the only topical antiangiogenic agent tested in phase II and III trials is aganirsen.Administration of topical aganirsen eye drops (86 μg/d per eye) in patients with keratitis related progressive CNV has been shown to lead to significant amelioration of CNV and reduced need for corneal transplantation[23].Although these agents are effective in the treatment of actively growing vessels, they have limited efficacy in well-established CNV[24].

    Conbercept can both bind to placental growth factor and all isoforms of VEGF-A and VEGF-B[25].As it has multiple targets, strong affinity, and a long half-life cycle, conbercept has proved to be effective and safe in the treatment of diabetic macular edema[26].In cases of refractory macular edema secondary to central retinal vein occlusion (CRVO), after switching from bevacizumab/ranibizumab, conbercept can improve macular thickness and extend interval of injection[27].Duet al[28]confirmed that conbercept, especially early administration, can effectively inhibit CNV in rabbits, intrastromal administrations has the better effect than subconjunctival injection.

    The present study used conbercept in patients with CNV and showed that the area of CNV reduced significantly already one day after treatment whereas the length and diameter of CNV reduced significantly one week after treatment.As the reduction in all three parameters peaked at two weeks after treatment, it might be beneficial to administer new injections to maintain or enhance effectiveness.For instance, although there were still significant reductions in all three indicators at one month after treatment, compared to the pre-treatment period,the magnitude of reductions diminished compared to two weeks after treatment.The observation time of this study was only 1mo, and it is speculated that with the extension of time(such as 3mo), the CNV may recur, suggesting the potential need of repeated treatments[15].Alternatively, for patients with stable CNV, transplantation of corneal graft might be considered at this time point, with the aim to achieve the best treatment effect for reducing neovascularization.

    Although all patients in the present study demonstrated a reduction in CNV after treatment, the reduction varied in magnitude and none of the patients had a complete resolution.There are multiple potential explanations for the partial effectiveness.First, the dosage administered in the present treatment is not sufficient to completely antagonize the corneal VEGF burden.Second, we only injected conbercept once and this might have led to a low cumulative concentration of the medication.Third, cytokines other than VEGF, such as transforming growth factor-α, transforming growth factor-β1,and fibroblast growth factor, can also induce CNV[29]and are not targeted by conbercept.Because neovascularization likely involves multiple processes, targeting VEGF alone might prevent the pro-angiogenic cascade but not others.Finally,conbercept works mostly on newly formed blood vessels,whereas our case series included patients with CNV due to different reasons and patients with both newly formed and long-standing neovascularization.As a result, some of the patients included in this study had more severe CNV with more mature vessels.As discussed above, the limited number of treatments might have also affected the treatment effectiveness.Previous evidence suggests that VEGF inhibitors can influence corneal healing by interfering with macrophage infiltration[30].Soleimaniet al[31]reported two cases with Descemet membrane detachment after intrastromal bevacizumab injection in patients with previous lamellar keratoplasty.The hemorrhagic Descemet membrane detachment was not resolved, the donor had to exchange with a new one because of staining in one of the patients.We should emphasize that the complications were not related to bevacizumab, instead the injection method was involved in these situations.In this study, we injected conbercept in the corneoscleral limbus near the root of the CNV to avoid damaging the corneal tissue.The subconjunctival injection may be a safer method, and the medication can however diffuse in a short distance through the conjunctival tissue to the central blood vessels.There was no thinning of the corneal epithelium or stroma, injury in corneal epithelium, conjunctivitis, keratitis, endophthalmitis,cataract, or other complications, demonstrating the safety of subconjunctival conbercept.

    In conclusion, subconjunctival conbercept may be an effective and safe option for the treatment of CNV, significantly reducing the area, length, and diameter of CNV without severe complications.Conbercept may also be considered an adjunct to other medical or surgical treatments of CNV.The use of conbercept for CNV is however still off-label.Further studies with a larger number of patients and longer followup are needed to validate our findings and to optimize the treatment regimen (e.g., number and timing of injections as well as injections versus other routes of administration).Comparison studies with other anti-VEGF agents are also helpful.

    ACKNOWLEDGEMENTS

    Foundation:Supported by the National Natural Science Foundation of China (No.81970764); the Youth Beijing Scholar (No.2020-022).

    Conflicts of Interest:Sun C, None; Ruan F, None; Li S,None; Zhang JQ, None; Jie Y, None.

    亚洲精品国产av蜜桃| 两性夫妻黄色片 | 丰满少妇做爰视频| 女的被弄到高潮叫床怎么办| 欧美日本中文国产一区发布| 国产精品偷伦视频观看了| 亚洲美女视频黄频| 精品少妇内射三级| 免费黄网站久久成人精品| 国产精品人妻久久久久久| 国产免费一级a男人的天堂| 少妇人妻 视频| 看免费av毛片| 纯流量卡能插随身wifi吗| 少妇的逼水好多| 在线看a的网站| 搡女人真爽免费视频火全软件| 日韩成人av中文字幕在线观看| 亚洲国产精品成人久久小说| 欧美精品高潮呻吟av久久| av有码第一页| 国产成人免费观看mmmm| av不卡在线播放| 新久久久久国产一级毛片| 亚洲经典国产精华液单| 成人国产av品久久久| 一级毛片 在线播放| 91精品国产国语对白视频| 亚洲精品中文字幕在线视频| 五月开心婷婷网| 欧美人与性动交α欧美精品济南到 | 中文欧美无线码| 激情五月婷婷亚洲| 免费黄色在线免费观看| 国产毛片在线视频| 69精品国产乱码久久久| av卡一久久| 18禁动态无遮挡网站| 欧美激情 高清一区二区三区| 久久免费观看电影| 丰满迷人的少妇在线观看| 秋霞在线观看毛片| 18禁国产床啪视频网站| 亚洲天堂av无毛| 在线观看美女被高潮喷水网站| 三级国产精品片| 国产精品人妻久久久久久| 最新的欧美精品一区二区| 中文字幕最新亚洲高清| 晚上一个人看的免费电影| 欧美人与善性xxx| 大香蕉久久成人网| 校园人妻丝袜中文字幕| 亚洲精品国产av蜜桃| 亚洲中文av在线| 看非洲黑人一级黄片| 欧美日韩视频高清一区二区三区二| 国产亚洲一区二区精品| 岛国毛片在线播放| 一本—道久久a久久精品蜜桃钙片| 人妻人人澡人人爽人人| 久久久a久久爽久久v久久| 国产av一区二区精品久久| 欧美激情国产日韩精品一区| 国产高清不卡午夜福利| 日本与韩国留学比较| 亚洲av男天堂| 黄片播放在线免费| 最近手机中文字幕大全| 秋霞在线观看毛片| 精品少妇黑人巨大在线播放| 一区二区av电影网| 国产亚洲精品久久久com| 91成人精品电影| 香蕉丝袜av| 爱豆传媒免费全集在线观看| 老司机影院成人| 久久精品熟女亚洲av麻豆精品| 边亲边吃奶的免费视频| 久久久久久久精品精品| 男人舔女人的私密视频| 成年美女黄网站色视频大全免费| 日韩av免费高清视频| 下体分泌物呈黄色| 国产成人一区二区在线| 欧美日韩视频精品一区| 亚洲国产最新在线播放| 两个人免费观看高清视频| 日韩一本色道免费dvd| av一本久久久久| a级毛色黄片| 久久久久久久久久成人| av片东京热男人的天堂| 丝袜脚勾引网站| 亚洲人成网站在线观看播放| 日本午夜av视频| 国产免费视频播放在线视频| 韩国精品一区二区三区 | 亚洲欧美中文字幕日韩二区| 深夜精品福利| 极品人妻少妇av视频| 精品久久久精品久久久| 80岁老熟妇乱子伦牲交| 美女主播在线视频| 国产精品久久久久久av不卡| 国产淫语在线视频| freevideosex欧美| 国产综合精华液| 中文字幕制服av| 亚洲av电影在线进入| 桃花免费在线播放| 人妻少妇偷人精品九色| 欧美+日韩+精品| 久久精品久久久久久噜噜老黄| 亚洲婷婷狠狠爱综合网| 成年女人在线观看亚洲视频| 丰满乱子伦码专区| 欧美成人精品欧美一级黄| 久久久久久久久久久免费av| 国产精品免费大片| 久热久热在线精品观看| 人人妻人人澡人人爽人人夜夜| 七月丁香在线播放| 国产精品一区www在线观看| kizo精华| av免费在线看不卡| 在线免费观看不下载黄p国产| 尾随美女入室| 少妇人妻 视频| 亚洲四区av| 国产av一区二区精品久久| av播播在线观看一区| 91精品国产国语对白视频| 免费黄频网站在线观看国产| a级毛片在线看网站| 国产综合精华液| 久久精品国产亚洲av天美| 你懂的网址亚洲精品在线观看| 777米奇影视久久| 午夜激情av网站| 色5月婷婷丁香| 久久精品久久久久久噜噜老黄| av电影中文网址| 免费人成在线观看视频色| 亚洲精品,欧美精品| 免费观看无遮挡的男女| 久久婷婷青草| 亚洲天堂av无毛| 日韩欧美精品免费久久| 精品人妻在线不人妻| av播播在线观看一区| 精品少妇内射三级| 日韩在线高清观看一区二区三区| 又大又黄又爽视频免费| 午夜激情av网站| 亚洲精品美女久久久久99蜜臀 | 日韩一区二区视频免费看| 18在线观看网站| 中文字幕av电影在线播放| 国产亚洲av片在线观看秒播厂| av网站免费在线观看视频| 免费大片18禁| 国产免费又黄又爽又色| 99香蕉大伊视频| 精品久久久精品久久久| 亚洲久久久国产精品| 精品一区二区三区四区五区乱码 | 国产有黄有色有爽视频| 久久综合国产亚洲精品| 一个人免费看片子| 日本午夜av视频| 99久久精品国产国产毛片| 少妇被粗大的猛进出69影院 | 99热这里只有是精品在线观看| 精品酒店卫生间| 精品久久蜜臀av无| 中文字幕制服av| 男女免费视频国产| 少妇猛男粗大的猛烈进出视频| 国产xxxxx性猛交| 大香蕉久久成人网| 亚洲欧美清纯卡通| 久久鲁丝午夜福利片| 精品午夜福利在线看| 妹子高潮喷水视频| 制服丝袜香蕉在线| 国产成人a∨麻豆精品| 亚洲国产看品久久| 国产一区二区在线观看av| 人妻少妇偷人精品九色| 波野结衣二区三区在线| 久久综合国产亚洲精品| 精品视频人人做人人爽| 少妇人妻久久综合中文| 久久精品久久久久久久性| 黑丝袜美女国产一区| 亚洲欧洲日产国产| 男女午夜视频在线观看 | 内地一区二区视频在线| 日产精品乱码卡一卡2卡三| 99久久综合免费| 午夜免费观看性视频| 亚洲熟女精品中文字幕| 国内精品宾馆在线| 日韩熟女老妇一区二区性免费视频| 亚洲av福利一区| 国产精品蜜桃在线观看| 母亲3免费完整高清在线观看 | 久久久精品94久久精品| 建设人人有责人人尽责人人享有的| 不卡视频在线观看欧美| 高清av免费在线| 久久久久久久国产电影| 午夜日本视频在线| 大香蕉97超碰在线| 国产成人精品在线电影| 观看美女的网站| 久久国产精品男人的天堂亚洲 | 少妇人妻精品综合一区二区| 我的女老师完整版在线观看| 黑人巨大精品欧美一区二区蜜桃 | 51国产日韩欧美| 亚洲,欧美,日韩| xxx大片免费视频| 在线免费观看不下载黄p国产| 国产精品一区二区在线观看99| www.熟女人妻精品国产 | 欧美另类一区| 丝袜喷水一区| 婷婷色综合大香蕉| 丰满饥渴人妻一区二区三| 九九在线视频观看精品| 亚洲精品久久午夜乱码| 午夜视频国产福利| 中文字幕人妻熟女乱码| 51国产日韩欧美| 国产av精品麻豆| 在线观看美女被高潮喷水网站| 久久久久久久亚洲中文字幕| 精品国产一区二区久久| 一级黄片播放器| 国产精品久久久久久久电影| av国产精品久久久久影院| h视频一区二区三区| 一区二区av电影网| 女的被弄到高潮叫床怎么办| 日本与韩国留学比较| 在现免费观看毛片| 黄色一级大片看看| 天堂8中文在线网| 国产xxxxx性猛交| 日韩不卡一区二区三区视频在线| 蜜桃国产av成人99| 2022亚洲国产成人精品| 国产 精品1| 久久国产精品大桥未久av| 亚洲国产精品一区三区| 国产精品国产av在线观看| 美女国产视频在线观看| 久久久久久人妻| 这个男人来自地球电影免费观看 | 少妇猛男粗大的猛烈进出视频| 亚洲精品久久成人aⅴ小说| 久久久久精品久久久久真实原创| 欧美亚洲日本最大视频资源| 成人毛片a级毛片在线播放| 热re99久久国产66热| 久久久欧美国产精品| 爱豆传媒免费全集在线观看| 国产日韩欧美亚洲二区| 极品人妻少妇av视频| 婷婷成人精品国产| 18在线观看网站| 色婷婷久久久亚洲欧美| 人人妻人人澡人人爽人人夜夜| av天堂久久9| 久久国产精品男人的天堂亚洲 | 久久这里有精品视频免费| 亚洲av男天堂| 亚洲精品一区蜜桃| 亚洲欧洲国产日韩| 狠狠精品人妻久久久久久综合| 亚洲精品自拍成人| 中文字幕精品免费在线观看视频 | 久久久久精品性色| 亚洲第一区二区三区不卡| 高清不卡的av网站| 免费看光身美女| 91久久精品国产一区二区三区| 亚洲国产毛片av蜜桃av| 日日撸夜夜添| 18禁动态无遮挡网站| 免费高清在线观看视频在线观看| 狂野欧美激情性bbbbbb| 欧美精品人与动牲交sv欧美| 在现免费观看毛片| 制服丝袜香蕉在线| av不卡在线播放| 久久国产精品大桥未久av| 啦啦啦中文免费视频观看日本| 国产又色又爽无遮挡免| 伦理电影免费视频| 午夜视频国产福利| 久久久精品94久久精品| 午夜视频国产福利| www.熟女人妻精品国产 | 精品少妇久久久久久888优播| 另类亚洲欧美激情| 久久久精品94久久精品| 少妇的逼水好多| 久久久国产一区二区| 91成人精品电影| 精品国产一区二区久久| 99久久人妻综合| 男人操女人黄网站| 欧美亚洲日本最大视频资源| 亚洲天堂av无毛| 国产精品一二三区在线看| 男女啪啪激烈高潮av片| 51国产日韩欧美| 边亲边吃奶的免费视频| 国产 精品1| 亚洲欧美一区二区三区黑人 | 精品亚洲成国产av| 七月丁香在线播放| 久久久a久久爽久久v久久| 日韩制服骚丝袜av| 亚洲精品一区蜜桃| av片东京热男人的天堂| 乱码一卡2卡4卡精品| 日韩不卡一区二区三区视频在线| 黑人巨大精品欧美一区二区蜜桃 | 夜夜爽夜夜爽视频| av又黄又爽大尺度在线免费看| 伊人久久国产一区二区| 日本vs欧美在线观看视频| 免费黄网站久久成人精品| 五月伊人婷婷丁香| 飞空精品影院首页| 日韩精品有码人妻一区| 女的被弄到高潮叫床怎么办| 观看av在线不卡| 欧美成人午夜精品| 两性夫妻黄色片 | 22中文网久久字幕| 亚洲欧美日韩另类电影网站| 这个男人来自地球电影免费观看 | www日本在线高清视频| 99视频精品全部免费 在线| 国产1区2区3区精品| 精品少妇黑人巨大在线播放| 黄片播放在线免费| 亚洲国产日韩一区二区| 少妇猛男粗大的猛烈进出视频| 国产欧美亚洲国产| 久久韩国三级中文字幕| 国产高清不卡午夜福利| 婷婷色综合www| 在线天堂最新版资源| 最后的刺客免费高清国语| 国产精品一区二区在线观看99| 在线观看免费高清a一片| 性高湖久久久久久久久免费观看| 久久午夜福利片| 久久久国产精品麻豆| 91精品伊人久久大香线蕉| 少妇高潮的动态图| av国产久精品久网站免费入址| 国产白丝娇喘喷水9色精品| 卡戴珊不雅视频在线播放| 成年人免费黄色播放视频| av国产精品久久久久影院| 在线天堂中文资源库| 免费观看性生交大片5| 99re6热这里在线精品视频| 国产精品女同一区二区软件| 91精品三级在线观看| 亚洲精品久久午夜乱码| 久久久国产精品麻豆| 99久久综合免费| 久久久久久久久久人人人人人人| 国产精品久久久久成人av| 夫妻性生交免费视频一级片| 日韩免费高清中文字幕av| 亚洲人成77777在线视频| 9191精品国产免费久久| 国产成人午夜福利电影在线观看| 激情五月婷婷亚洲| 高清视频免费观看一区二区| 一区二区三区四区激情视频| 国产男女超爽视频在线观看| av不卡在线播放| 男女下面插进去视频免费观看 | 只有这里有精品99| 晚上一个人看的免费电影| 免费在线观看黄色视频的| 精品99又大又爽又粗少妇毛片| 最新中文字幕久久久久| 在线观看人妻少妇| 又粗又硬又长又爽又黄的视频| 日韩精品免费视频一区二区三区 | 熟妇人妻不卡中文字幕| 色婷婷av一区二区三区视频| 天天影视国产精品| 免费久久久久久久精品成人欧美视频 | 黄色配什么色好看| 精品卡一卡二卡四卡免费| 国产精品一区二区在线观看99| 一级毛片我不卡| 国产免费福利视频在线观看| 久久久久国产精品人妻一区二区| 香蕉国产在线看| 久热久热在线精品观看| 精品一区二区三区四区五区乱码 | 国产精品秋霞免费鲁丝片| 亚洲av在线观看美女高潮| 桃花免费在线播放| 精品一区二区三卡| 久久影院123| 国产一区二区三区综合在线观看 | 纵有疾风起免费观看全集完整版| 熟女人妻精品中文字幕| 成人手机av| 亚洲精品国产av蜜桃| 色婷婷av一区二区三区视频| 成年女人在线观看亚洲视频| 久久人人爽av亚洲精品天堂| 色94色欧美一区二区| 美国免费a级毛片| 国产福利在线免费观看视频| 三级国产精品片| 欧美日韩精品成人综合77777| 乱人伦中国视频| 最近最新中文字幕免费大全7| 日本欧美视频一区| 久久午夜综合久久蜜桃| 女人久久www免费人成看片| 国产免费一区二区三区四区乱码| 亚洲国产精品一区二区三区在线| 国产 精品1| 91国产中文字幕| 三上悠亚av全集在线观看| 亚洲国产av新网站| 一个人免费看片子| 国产亚洲最大av| 国产精品人妻久久久久久| 久久久国产一区二区| 久久久国产欧美日韩av| 成人国产麻豆网| 丰满饥渴人妻一区二区三| 狠狠婷婷综合久久久久久88av| 中文字幕最新亚洲高清| 91成人精品电影| 大香蕉久久成人网| 国产亚洲精品久久久com| 国产在线免费精品| 久久热在线av| 久久久精品免费免费高清| 精品午夜福利在线看| 免费黄网站久久成人精品| 日本色播在线视频| 99热全是精品| 欧美精品人与动牲交sv欧美| 国语对白做爰xxxⅹ性视频网站| 乱码一卡2卡4卡精品| 少妇人妻 视频| 国产日韩欧美在线精品| 国产高清国产精品国产三级| 国产成人精品福利久久| 亚洲四区av| 1024视频免费在线观看| 如何舔出高潮| 各种免费的搞黄视频| av视频免费观看在线观看| 午夜免费鲁丝| 肉色欧美久久久久久久蜜桃| 国产乱来视频区| 国产一区二区在线观看日韩| 国产高清三级在线| 狂野欧美激情性xxxx在线观看| 国产欧美亚洲国产| 在现免费观看毛片| 国产一区二区三区av在线| 97在线人人人人妻| 男女国产视频网站| av有码第一页| 亚洲国产色片| 美女主播在线视频| 夜夜爽夜夜爽视频| 亚洲精品久久午夜乱码| 日本-黄色视频高清免费观看| 在线免费观看不下载黄p国产| 久久精品国产自在天天线| 国产日韩欧美在线精品| 黄片播放在线免费| 中文字幕人妻丝袜制服| 天堂俺去俺来也www色官网| 国产一区二区在线观看av| 亚洲精品久久成人aⅴ小说| 精品少妇久久久久久888优播| 全区人妻精品视频| 韩国av在线不卡| 欧美日韩视频精品一区| 一级爰片在线观看| 视频中文字幕在线观看| 免费观看在线日韩| 国产无遮挡羞羞视频在线观看| 女人精品久久久久毛片| 国产精品不卡视频一区二区| 亚洲婷婷狠狠爱综合网| 视频在线观看一区二区三区| av线在线观看网站| 多毛熟女@视频| 五月开心婷婷网| 亚洲欧美中文字幕日韩二区| 久久精品国产自在天天线| 国产色婷婷99| 91在线精品国自产拍蜜月| 天堂中文最新版在线下载| 欧美丝袜亚洲另类| 亚洲精品色激情综合| 高清视频免费观看一区二区| 欧美 亚洲 国产 日韩一| 欧美日韩成人在线一区二区| 丁香六月天网| 欧美性感艳星| 免费女性裸体啪啪无遮挡网站| 久久久精品区二区三区| 久久久久视频综合| 99国产精品免费福利视频| 亚洲四区av| 免费观看a级毛片全部| 久久久久久久亚洲中文字幕| 黄色怎么调成土黄色| 欧美日韩一区二区视频在线观看视频在线| a级毛色黄片| 精品国产乱码久久久久久小说| 自线自在国产av| 99久久中文字幕三级久久日本| 国产又色又爽无遮挡免| 亚洲高清免费不卡视频| 精品熟女少妇av免费看| 国产精品一区www在线观看| 日本av免费视频播放| 久久久久久久亚洲中文字幕| 免费观看性生交大片5| 午夜福利网站1000一区二区三区| 午夜精品国产一区二区电影| 国产精品免费大片| 国产精品一区二区在线观看99| 少妇人妻精品综合一区二区| 亚洲av男天堂| 欧美人与善性xxx| 色婷婷久久久亚洲欧美| 日韩伦理黄色片| 两个人免费观看高清视频| 大片免费播放器 马上看| 婷婷色麻豆天堂久久| 乱码一卡2卡4卡精品| 黄片播放在线免费| 亚洲一码二码三码区别大吗| 久久久久久久国产电影| 男女高潮啪啪啪动态图| 国产av码专区亚洲av| 婷婷色av中文字幕| 一级片'在线观看视频| 黄色一级大片看看| 少妇人妻精品综合一区二区| 桃花免费在线播放| 精品少妇黑人巨大在线播放| av女优亚洲男人天堂| 亚洲av成人精品一二三区| 18+在线观看网站| 咕卡用的链子| 一区二区三区精品91| 一级爰片在线观看| 国产1区2区3区精品| 亚洲一区二区三区欧美精品| 免费黄频网站在线观看国产| 91在线精品国自产拍蜜月| 一级片免费观看大全| av黄色大香蕉| 在线观看美女被高潮喷水网站| 国产成人精品无人区| 丝瓜视频免费看黄片| 久久热在线av| 久久99一区二区三区| 国产爽快片一区二区三区| 久久ye,这里只有精品| av.在线天堂| 纯流量卡能插随身wifi吗| 亚洲精品国产色婷婷电影| av.在线天堂| 三上悠亚av全集在线观看| 欧美精品av麻豆av| 制服丝袜香蕉在线| 亚洲美女搞黄在线观看| 亚洲av电影在线观看一区二区三区| 大话2 男鬼变身卡| 男女边摸边吃奶| 国产亚洲av片在线观看秒播厂| 最近中文字幕高清免费大全6| 日韩一本色道免费dvd| 免费黄频网站在线观看国产| 高清不卡的av网站| 最新的欧美精品一区二区| 亚洲国产毛片av蜜桃av| 卡戴珊不雅视频在线播放| 一区二区三区精品91| 日韩精品免费视频一区二区三区 | 欧美+日韩+精品| 国产黄色视频一区二区在线观看| 国产成人免费观看mmmm| 久久鲁丝午夜福利片| 少妇熟女欧美另类|